Article ; Online: Quantitative Delta T1 (dT1) as a Replacement for Adjudicated Central Reader Analysis of Contrast-Enhancing Tumor Burden: A Subanalysis of the American College of Radiology Imaging Network 6677/Radiation Therapy Oncology Group 0625 Multicenter Brain Tumor Trial.
AJNR. American journal of neuroradiology
2019 Volume 40, Issue 7, Page(s) 1132–1139
Abstract: Background and purpose: Brain tumor clinical trials requiring solid tumor assessment typically rely on the 2D manual delineation of enhancing tumors by ≥2 expert readers, a time-consuming step with poor interreader agreement. As a solution, we developed ...
Abstract | Background and purpose: Brain tumor clinical trials requiring solid tumor assessment typically rely on the 2D manual delineation of enhancing tumors by ≥2 expert readers, a time-consuming step with poor interreader agreement. As a solution, we developed quantitative dT1 maps for the delineation of enhancing lesions. This retrospective analysis compares dT1 with 2D manual delineation of enhancing tumors acquired at 2 time points during the post therapeutic surveillance period of the American College of Radiology Imaging Network 6677/Radiation Therapy Oncology Group 0625 (ACRIN 6677/RTOG 0625) clinical trial. Materials and methods: Patients enrolled in ACRIN 6677/RTOG 0625, a multicenter, randomized Phase II trial of bevacizumab in recurrent glioblastoma, underwent standard MR imaging before and after treatment initiation. For 123 patients from 23 institutions, both 2D manual delineation of enhancing tumors and dT1 datasets were evaluable at weeks 8 ( Results: For identification of progression, dT1 and adjudicated 2D manual delineation of enhancing tumor reads were in perfect agreement at week 8, with 73.7% agreement at week 16. Both methods showed significant differences in overall survival at each time point. When nonprogressors were further divided into responders versus nonresponders/nonprogressors, the agreement decreased to 70.3% and 52.6%, yet dT1 showed a significant difference in overall survival at week 8 ( Conclusions: This study shows that dT1 can predict early progression comparable with the standard method but offers the potential for substantial time and cost savings for clinical trials. |
---|---|
MeSH term(s) | Adult ; Aged ; Antineoplastic Agents, Immunological/therapeutic use ; Bevacizumab/therapeutic use ; Brain Neoplasms/diagnostic imaging ; Brain Neoplasms/drug therapy ; Brain Neoplasms/pathology ; Female ; Glioblastoma/diagnostic imaging ; Glioblastoma/drug therapy ; Glioblastoma/pathology ; Humans ; Image Interpretation, Computer-Assisted/methods ; Magnetic Resonance Imaging/methods ; Male ; Middle Aged ; Neuroimaging/methods ; Retrospective Studies ; Tumor Burden |
Chemical Substances | Antineoplastic Agents, Immunological ; Bevacizumab (2S9ZZM9Q9V) |
Language | English |
Publishing date | 2019-06-27 |
Publishing country | United States |
Document type | Clinical Trial, Phase II ; Journal Article ; Multicenter Study ; Randomized Controlled Trial ; Research Support, Non-U.S. Gov't |
ZDB-ID | 603808-6 |
ISSN | 1936-959X ; 0195-6108 |
ISSN (online) | 1936-959X |
ISSN | 0195-6108 |
DOI | 10.3174/ajnr.A6110 |
Database | MEDical Literature Analysis and Retrieval System OnLINE |
More links
Kategorien
In stock of ZB MED Cologne/Königswinter
Zs.A 1580: Show issues | Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG) |
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.